American Society of Hematology Annual Meeting

Momentum and Meaning at the 2025 American Society of Hematology Meeting

December 24th 2025, 10:00pm

Video

CURE was on site at the 2025 ASH Annual Meeting, sharing expert conversations and patient-focused reporting that highlighted progress in blood cancer care.

Key Blood Cancer Advances for Patients From the 2025 ASH Annual Meeting

December 16th 2025, 10:00pm

Article

At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients with blood cancers are treated.

Suleika Jaouad, Reporting From the Front Lines of Leukemia

December 12th 2025, 2:00pm

Video

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

What Does Minimal Residual Disease Mean?

December 11th 2025, 9:00pm

Article

CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma.

Momelotinib Combo is Safe and Helps Ease Symptoms in Myelofibrosis

December 10th 2025, 9:48pm

Article

Nuvisertib plus momelotinib is safe and generated improvements in symptom burden, spleen volume, and anemia outcomes in relapsed/refractory myelofibrosis.

Suleika Jaouad Celebrates Blood Cancer Heroes With CURE and Blood Cancer United

December 10th 2025, 2:00pm

Video

Emmy-winning journalist and author, Suleika Jaouad, delivered the keynote address at the inaugural Blood Cancer Heroes event.

Off-The-Shelf CAR-T KLN-1010 Associated With Deep Responses in R/R Myeloma

December 10th 2025, 12:12am

Article

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

Yescarta Shows Durable Responses and Manageable Safety in Real-World R/R FL

December 9th 2025, 9:10pm

Article

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dexamethasone May Ease Severe Neurotoxicity With Yescarta in LBCL

December 9th 2025, 6:10pm

Article

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

New Data Support Pelabresib Combination in Untreated Myelofibrosis

December 9th 2025, 5:29pm

Article

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.